Dr Cindy Chu
Contact information
Cindy Chu
Clinical researcher
Cindy’s main research area is in Plasmodium vivax malaria. She has conducted studies on the epidemiology of P. vivax recurrence as well as efficacy trials with the schizonticidal agents chloroquine and dihydroartemisinin-piperaquine. Her current focus is on the radical curative treatment of P. vivax using 8-aminoquinolines and the haemolytic effects of this class of drugs in G6PD heterozygous females. The goal of this research is for the safe delivery of primaquine and tafenoquine for treatment of P. vivax malaria and within the context of P. vivax elimination.
Chloroquine and primaquine induced haematocrit changes to G6PD heterozygote
Plasmodium vivax recurrences
Recent publications
-
Evaluation of the Wondfo G6PD/Hb Test for glucose-6-phosphate dehydrogenase deficiency: preliminary performance, matrix equivalence, and usability.
Journal article
Green RK. et al, (2025), Malaria journal, 24
-
Submicroscopic malaria in pregnancy and associated adverse pregnancy events: A case-cohort study of 4,352 women on the Thailand–Myanmar border
Journal article
Gilder ME. et al, (2025), PLOS Medicine, 22, e1004529 - e1004529
-
High-dose primaquine reduces vivax relapses: time for change.
Journal article
Commons RJ. and Chu CS., (2025), The Lancet. Infectious diseases
-
A mixed methods study investigating factors affecting adherence to Plasmodium vivax malaria primaquine radical cure regimens among migrants along the Myanmar-Thailand border
Journal article
Ansari AT. et al, (2025), PLOS Global Public Health, 5, e0003615 - e0003615
-
Primaquine for uncomplicated Plasmodium vivax malaria in children younger than 15 years: a systematic review and individual patient data meta-analysis
Journal article
Commons RJ. et al, (2024), The Lancet Child & Adolescent Health, 8, 798 - 808